Long‐term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5‐year data demonstrating clinical improvement with sustained efficacy

• Published in: Journal of dermatology Vol. 51; no. 5; pp. 684 - 690
• Main Authors: Choi, Sangmin, Kwon, Soon‐Hyo, Sim, Woo‐Young, Lew, Bark‐Lynn
• Format: Journal Article
• Language: English
• Published: England 01-05-2024
• Subjects: androgenetic alopecia; dutasteride; hair loss; male pattern baldness; pattern baldness; dutasteride; pattern baldness; hair loss; male pattern baldness; androgenetic alopecia
• ISSN: 0385-2407; 1346-8138
• DOI: 10.1111/1346-8138.17138

Dutasteride 0.5 mg is a dual inhibitor of 5α‐reductase type I and II and was approved in Korea in 2009 for treating androgenetic alopecia (AGA) in men. We investigated the 5‐year efficacy and safety of dutasteride 0.5 mg in Korean men with AGA using the basic and specific (BASP) classification. This retrospective analysis included 99 male AGA patients aged ≥18 years who were treated with dutasteride 0.5 mg for at least 5 years from October 2009 to December 2016 at Kyung Hee University Hospital in Gangdong. Patient photographs were scored using the BASP classification, and the Investigator Global Assessment (IGA) was performed using a seven‐point scale. Patient improvement (IGA score ≥1) and prevention of disease progression (IGA score ≥0) were 89.9% (89/99) and 93.9% (93/99), respectively. According to the BASP classification, 52.5% (52/99) of the basic type, 75% (15/20) of the specific F type, and 82.2% (60/73) of the specific V type showed clinical improvement after 5 years of treatment. Dutasteride demonstrated long‐term safety and efficacy in Korean male patients with AGA over a period of at least 5 years, with results comparable to those of other long‐term efficacy studies of finasteride 1 mg in male patients with AGA.